Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Giulia Benevolo, Francesco Vassallo, Irene Urbino & Valentina Giai. (2021) Polycythemia Vera (PV): Update on Emerging Treatment Options. Therapeutics and Clinical Risk Management 17, pages 209-221.
Read now
Read now
Achille Pich, Eloise Beggiato, Laura Godio, Ludovica Riera, Paola Francia di Celle, Giuseppe Lanzarone & Giulia Benevolo. (2021) Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms. Expert Review of Hematology 14:9, pages 841-850.
Read now
Read now
Niccolò Bartalucci, Paola Guglielmelli & Alessandro M. Vannucchi. (2020) Polycythemia vera: the current status of preclinical models and therapeutic targets. Expert Opinion on Therapeutic Targets 24:7, pages 615-628.
Read now
Read now
Lucia Masarova, Srdan Verstovsek, Hagop Kantarjian & Naval Daver. (2017) Immunotherapy based approaches in myelofibrosis. Expert Review of Hematology 10:10, pages 903-914.
Read now
Read now
Chad C Cherington, Krisstina L Gowin & Ruben A Mesa. (2015) Ruxolitinib for treatment of polycythemia vera. Expert Opinion on Orphan Drugs 3:9, pages 1085-1096.
Read now
Read now
Hans Carl Hasselbalch & Richard T Silver. (2015) Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. Expert Review of Hematology 8:4, pages 439-445.
Read now
Read now
Srdan Verstovsek & Rami S Komrokji. (2015) Novel and emerging therapies for the treatment of polycythemia vera. Expert Review of Hematology 8:1, pages 101-113.
Read now
Read now
Hans C Hasselbalch. (2014) Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Review of Hematology 7:2, pages 203-216.
Read now
Read now
Vibe Skov, Caroline Hasselbalch Riley, Mads Thomassen, Thomas Stauffer Larsen, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse & Hans Carl Hasselbalch. (2013) Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leukemia & Lymphoma 54:10, pages 2269-2273.
Read now
Read now
Richard T Silver, Jean-Jacques Kiladjian & Hans Carl Hasselbalch. (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology 6:1, pages 49-58.
Read now
Read now
Hans Carl Hasselbalch. (2011) A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Review of Hematology 4:6, pages 637-655.
Read now
Read now
Articles from other publishers (56)
Zi Yun Ng, Kathryn A. Fuller, Allegra Mazza‐Parton & Wendy N. Erber. (2023) Morphology of myeloproliferative neoplasms. International Journal of Laboratory Hematology 45:S2, pages 59-70.
Crossref
Crossref
Marc J. B. Dam, Rasmus K. Pedersen, Trine A. Knudsen, Morten Andersen, Christina Ellervik, Morten Kranker Larsen, Lasse Kjær, Vibe Skov, Hans C. Hasselbalch & Johnny T. Ottesen. (2022)
A novel integrated biomarker index for the assessment of hematological responses in
MPNs
during treatment with hydroxyurea and interferon‐alpha2
. Cancer Medicine 12:4, pages 4218-4226.
Crossref
Crossref
Hans Hasselbalch, Vibe Skov, Lasse Kjær, Morten Kranker Larsen, Trine A. Knudsen, Marko Lucijanić & Rajko Kusec. (2022) Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives. Cancers 14:22, pages 5495.
Crossref
Crossref
Narendranath Epperla, Walter Hanel & Moshe Talpaz. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
21
.
Vibe Skov, Mads Thomassen, Lasse Kjær, Christina Ellervik, Morten Kranker Larsen, Trine Alma Knudsen, Torben A. Kruse & Hans C. Hasselbalch. (2022) Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms. PLOS ONE 17:6, pages e0270669.
Crossref
Crossref
Trine Alma Knudsen, Vibe Skov, Kristen StevensonLillian WernerWilliam DukeCharles LauroreChristopher J. GibsonAnwesha NagAaron R. ThornerBruce Wollison, Dennis Lund Hansen, Christina Ellervik, Daniel El FassiKarin de StrickerLukas Frans OciasMette Brabrand, Ole Weis BjerrumUlrik Malthe OvergaardMikael FrederiksenThomas Kielsgaard KristensenTorben A. KruseMads ThomassenTorben Mourits-AndersenMarianne Tang Severinsen, Jesper StentoftJoern Starklint, Donna S. NeubergLasse Kjaer, Thomas Stauffer LarsenHans Carl Hasselbalch, R. Coleman Lindsley & Ann Mullally. (2022) Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances 6:7, pages 2107-2119.
Crossref
Crossref
Hans C. Hasselbalch & Richard T. Silver. (2021) New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. HemaSphere 5:12, pages e645.
Crossref
Crossref
Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Nikolai Podoltsev, Robert T. Williams, Martin S. Tallman, Raajit K. Rampal, Amer M. Zeidan & Maximilian Stahl. (2020) Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 35:6, pages 1643-1660.
Crossref
Crossref
Yajur Arya, Arshi Syal, Monica Gupta & Saurabh Gaba. (2021) Advances in the Treatment of Polycythemia Vera: Trends in Disease Management. Cureus.
Crossref
Crossref
Giacomo Coltro, Giuseppe G. Loscocco & Alessandro M. Vannucchi. 2021. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A. Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A
1
69
.
Moshe Talpaz, Jessica Mercer & Rüdiger Hehlmann. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
197
226
.
Jan Philipp Bewersdorf, Smith Giri, Rong Wang, Nikolai Podoltsev, Robert T. Williams, Raajit K. Rampal, Martin S. Tallman, Amer M. Zeidan & Maximilian Stahl. (2020) Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 20:10, pages e712-e723.
Crossref
Crossref
Vibe Skov. (2020) Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses. Cancers 12:8, pages 2194.
Crossref
Crossref
Morten Orebo Holmström, Hans Carl Hasselbalch & Mads Hald Andersen. (2020) Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers 12:7, pages 1763.
Crossref
Crossref
Michiels Jan Jacques, Lam King H, Kate Fibo Ten, Kim Dong-Wook, Kim Myungshin, Shuvaev Vasily, Valster Francisca, Potters Vincent, Schroyens Wilfried, Andreescu Mihaela, Trifa Adrian, Pich Achille & De Raeve Hendrik. (2020) Novel European Asiatic Clinical, Laboratory, Molecular and Pathobiological (2015-2020 CLMP) criteria for JAK2V617F trilinear polycythemia vera (PV), JAK2exon12 PV and JAK2V617F, CALR and MPL515 thrombocythemias: From Dameshek to Constantinescu-Vainchenker, Kralovics and Michiels. International Journal of Bone Marrow Research 3:1, pages 001-020.
Crossref
Crossref
Rasmus K. Pedersen, Morten Andersen, Trine A. Knudsen, Zamra Sajid, Johanne Gudmand‐Hoeyer, Marc J. B. Dam, Vibe Skov, Lasse Kjær, Christina Ellervik, Thomas S. Larsen, Dennis Hansen, Niels Pallisgaard, Hans C. Hasselbalch & Johnny T. Ottesen. (2020)
Data‐driven analysis of
JAK2
V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms
. Cancer Medicine 9:6, pages 2039-2051.
Crossref
Crossref
Jarmila Kissová. (2019) Interferon-alpha in the treatment of myeloproliferative diseases. Vnitřní lékařství 65:11, pages 699-703.
Crossref
Crossref
Lucia Masarova, Prithviraj Bose & Srdan Verstovsek. (2019) The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports 14:4, pages 310-327.
Crossref
Crossref
Mary Frances McMullin, Claire N. Harrison, Sahra Ali, Catherine Cargo, Frederick Chen, Joanne Ewing, Mamta Garg, Anna Godfrey, Steven Knapper S, Donal P. McLornan, Jyoti Nangalia, Mallika Sekhar, Frances Wadelin & Adam J. Mead. (2018) A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology 184:2, pages 176-191.
Crossref
Crossref
Hans Carl Hasselbalch & Morten Orebo Holmström. (2018) Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology 41:1, pages 5-19.
Crossref
Crossref
. (2018) Novel Clinical, Laboratory, Molecular and Pathological (2018 CLMP) Criteria
for the Differential Diagnosis of three Distinct JAK2, CALR and MPL Mutated
Myeloproliferative Neoplasms: The Role of Driver Mutation Analysis and Bone
Marrow Histology. International Journal of Cancer Research & Therapy 3:2.
Crossref
Crossref
Stine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, Trine Alma Knudsen, Anders Lindholm Sørensen, Christen Bertel Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Niels Pallisgaard, Mads Thomassen, Vibe Skov & Hans Carl Hasselbalch. (2018) Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine 7:8, pages 3571-3581.
Crossref
Crossref
A L MELIKYAN, I N SUBORTSEVA, E A GILYAZITDINOVA, T I KOLOSHEJNOVA, E I PUSTOVAYA, E K EGOROVA, A M KOVRIGINA, A B SUDARIKOV, A O ABDULLAEV, E G LOMAIA, N T SIORDIYA, A Yu ZARITSKEY & V G SAVCHENKO. (2018) Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. Terapevticheskii arkhiv 90:7, pages 23-29.
Crossref
Crossref
Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos & Srdan Verstovsek. (2017) Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Experimental Hematology & Oncology 6:1.
Crossref
Crossref
Charles Elliott Foucar & Brady Lee Stein. (2017) Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports 12:5, pages 406-414.
Crossref
Crossref
Lucia Masarova, Keyur P Patel, Kate J Newberry, Jorge Cortes, Gautam Borthakur, Marina Konopleva, Zeev Estrov, Hagop Kantarjian & Srdan Verstovsek. (2017) Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. The Lancet Haematology 4:4, pages e165-e175.
Crossref
Crossref
Adam J. Mead & Ann Mullally. (2017) Myeloproliferative neoplasm stem cells. Blood 129:12, pages 1607-1616.
Crossref
Crossref
Iben Onsberg Hansen, Anders Lindholm Sørensen & Hans Carl Hasselbalch. (2017) Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. European Journal of Haematology 98:1, pages 75-84.
Crossref
Crossref
M A Sokolova, A G Turkina, A L Melikian, A B Sudarikov, S A Treglazova, O A Shukhov, E G Gemdzhian, A О Abdullaev, A M Kovrigina, A V Misyurin, Yu V Pliskunova, V L Ivanova & T N Moiseeva. (2016) Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera. Terapevticheskii arkhiv 88:12, pages 69-77.
Crossref
Crossref
Caroline H. Riley, Marie K. Brimnes, Morten Hansen, Morten Krogh Jensen, Hans C. Hasselbalch, Lasse Kjaer, Per thor Straten & Inge Marie Svane. (2016) Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. European Journal of Haematology 97:1, pages 83-92.
Crossref
Crossref
H.C. Hasselbalch. (2016) Interferon-alfa – 30 years of clinical experience. Leukemia Research 44, pages S3-S4.
Crossref
Crossref
J-J Kiladjian, S Giraudier & B Cassinat. (2015) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30:4, pages 776-781.
Crossref
Crossref
Moshe Talpaz, Jessica Mercer & Rüdiger Hehlmann. 2016. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
207
230
.
. (2015) Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis. New England Journal of Medicine 373:26, pages 2579-2581.
Crossref
Crossref
Srdan VerstovsekHans Carl Hasselbalch. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment
86
102
.
Olga Pozdnyakova, Robert P. Hasserjian, Srdan Verstovsek & Attilio Orazi. (2015) Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome–Negative Myeloproliferative Neoplasms. Clinical Lymphoma Myeloma and Leukemia 15:5, pages 253-261.
Crossref
Crossref
Na Xu, Li Ding, Changxin Yin, Xuan Zhou, Lin Li, Yulin Li, Qisi Lu & Xiao-li Liu. (2014) A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients. Annals of Hematology 94:5, pages 865-867.
Crossref
Crossref
Caroline H. Riley, Morten Hansen, Marie K. Brimnes, Hans C. Hasselbalch, Ole W. Bjerrum, Per thor Straten, Inge Marie Svane & Morten Krogh Jensen. (2014)
Expansion of circulating CD56
bright
natural killer cells in patients with JAK2‐positive chronic myeloproliferative neoplasms during treatment with interferon‐α
. European Journal of Haematology 94:3, pages 227-234.
Crossref
Crossref
Mads Emil Bjørn & Hans Carl Hasselbalch. (2015) The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation 2015, pages 1-11.
Crossref
Crossref
Hans Carl Hasselbalch & Mads Emil Bjørn. (2015) MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation 2015, pages 1-16.
Crossref
Crossref
Edwin Chen & Ann Mullally. (2014) How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?. Hematology 2014:1, pages 268-276.
Crossref
Crossref
Bin-Tao Huang, Qing-Chun Zeng, Wei-Hong Zhao, Bing-Sheng Li & Rui-lin Chen. (2014) Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leukemia Research 38:10, pages 1177-1183.
Crossref
Crossref
M.E. Bjørn, K. de Stricker, L. Kjær, K. Ellemann & H.C. Hasselbalch. (2014) Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leukemia Research Reports 3:2, pages 73-75.
Crossref
Crossref
Thomas Stauffer Larsen, Katrine F. Iversen, Esben Hansen, Anders Bruun Mathiasen, Claus Marcher, Mikael Frederiksen, Herdis Larsen, Inge Helleberg, Caroline Hasselbalch Riley, Ole W. Bjerrum, Dorthe Rønnov-Jessen, Michael Boe Møller, Karin de Stricker, Hanne Vestergaard & Hans Carl Hasselbalch. (2013) Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leukemia Research 37:9, pages 1041-1045.
Crossref
Crossref
Richard T. Silver. (2013) Are All Interferons the Same for Therapy in Polycythemia Vera?. Clinical Lymphoma Myeloma and Leukemia 13, pages S305-S306.
Crossref
Crossref
Francesca PalandriNicola Polverelli, Lucia Catani, Michele Cavo & Nicola Vianelli. (2013) Update on the treatment of Ph-negative myeloproliferative neoplasms. International Journal of Hematologic Oncology 2:3, pages 251-262.
Crossref
Crossref
Ann MullallyClaudia BruedigamLuke PoveromoFlorian H. HeidelAmy PurdonTherese VuRebecca AustinDirk HecklLawrence J. BreyfogleCatherine Paine KuhnDemetrios Kalaitzidis, Scott A. Armstrong, David A. Williams, Geoff R. HillBenjamin L. EbertSteven W. Lane. (2013) Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood 121:18, pages 3692-3702.
Crossref
Crossref
Hans C. Hasselbalch. (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine & Growth Factor Reviews 24:2, pages 133-145.
Crossref
Crossref
Hans Carl Hasselbalch. (2013) Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?. Leukemia Research 37:2, pages 214-220.
Crossref
Crossref
Vibe Skov, Mads Thomassen, Caroline H. Riley, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse, Hans Carl Hasselbalch & Thomas Stauffer Larsen. (2012) Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology 40:9, pages 771-780.e19.
Crossref
Crossref
Jean-Jacques Kiladjian. 2012. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
85
92
.
Hans Carl Hasselbalch, Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K. Jensen, Ole Weis Bjerrum & Torben A. Kruse. (2011) High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leukemia Research 35:10, pages 1330-1334.
Crossref
Crossref
Caroline Hasselbalch RileyMorten Krogh Jensen, Marie Klinge BrimnesHans Carl HasselbalchOle Weis Bjerrum, Per thor StratenInge Marie Svane. (2011) Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α. Blood 118:8, pages 2170-2173.
Crossref
Crossref
Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Hasselbalch Riley, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse & Hans Carl Hasselbalch. (2011) Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. European Journal of Haematology 87:1, pages 54-60.
Crossref
Crossref
Hans Carl Hasselbalch, Jean-Jacques Kiladjian & Richard T. Silver. (2011) Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Journal of Clinical Oncology 29:18, pages e564-e565.
Crossref
Crossref
Jean-Jacques KiladjianRuben A. Mesa & Ronald Hoffman. (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117:18, pages 4706-4715.
Crossref
Crossref